Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-MRD-guided adaptive adjuvant tislelizumab study in ypN0 NSCLC after neoadjuvant chemoimmunotherapy
ChiCTR2500096565Phase 2Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: 2-year disease-free survival rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500096565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096565.